Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Nicklas Westerholm | Chief Executive Officer | 4.8M | -- | 1976 |
| Mr. Torsten Almén | Founder | -- | -- | -- |
| Dr. Ingemar Lundström Ph.D. | Founder | -- | -- | 1943 |
| Dr. Louis Joseph Ignarro Ph.D. | Founder | -- | -- | 1942 |
| Associate Prof. Heidi Brurok | Founder | -- | -- | -- |
| Dr. Rob Towart | Founder | -- | -- | -- |
| Dr. Yilmaz Mahshid Ph.D. | Chief Financial Officer | -- | -- | 1979 |
| Dr. Katayoun Welin-Berger Ph.D. | Vice President of Operations | -- | -- | 1968 |
| Dr. Jacques Näsström M.B.A., MBA, Ph.D. | Chief Scientific Officer | 655k | -- | 1959 |
| Dr. Karl Hard Ph.D. | VP and Head of Investor Relations & Communication | -- | -- | 1962 |
Egetis Therapeutics AB (publ)
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 40
Description
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company's products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
Corporate Governance
Upcoming Events
April 30, 2025 at 5:00 AM UTC
Egetis Therapeutics AB (publ) Earnings Date
Recent Events
Recent Events Information Not Available